

CITATION REPORT

List of articles citing

Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update

DOI: 10.1111/hepr.13411

Hepatology Research, 2019, 49, 1109-1113.

Source: <https://exaly.com/paper-pdf/72153106/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
316	Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study. <i>Hepatology Research</i> , 2020 , 50, 382-395	5.1	16
315	Surgical Resection: Old Dog, Any New Tricks?. 2020 , 24, 637-655		8
314	The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. 2020 , 14, 889-919		142
313	Clinical outcomes of direct-acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment. <i>Hepatology Research</i> , 2020 , 50, 1118-1127	5.1	8
312	A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma. 2020 , 9, 367-377		10
311	Two elder cases of hepatocellular carcinoma adjacent to intrahepatic vessels successfully treated by carbon ion radiotherapy. 2020 , 13, 920-926		1
310	Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. 2020 , 12,		10
309	Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination. 2020 , 52, 866-876		7
308	Impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study. 2020 , 52, 359-370		3
307	Treatment Selection for Early to Intermediate Hepatocellular Carcinoma. 2020 , 10, 4607		0
306	Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. 2020 , 12,		5
305	Hepatocellular Carcinoma: Eastern Experience. 2020 , 119-144		
304	Ultrasound Liver Imaging Reporting and Data System (US LI-RADS): An Overview with Technical and Practical Applications. 2021 , 28, 1464-1476		5
303	Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score. 2020 , 10, 13021		5
302	Treatment Strategy of Transarterial Chemoembolization for Hepatocellular Carcinoma. 2020 , 10, 7337		3
301	Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. <i>Hepatology Research</i> , 2020 , 50, 1375-1385	5.1	13
300	Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib. 2020 , 10, 5403		

299	Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. 2020 , 65, 3456-3462		7
298	Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia. 2020 , 122, 1587-1594		4
297	Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib. 2020 , 4, 1183-1190		2
296	Outcome of Hepatocellular Carcinoma Detected During Surveillance: Comparing USA and Japan. 2021 , 19, 2379-2388.e6		2
295	Validation of the GALAD Model and Establishment of GAAP Model for Diagnosis of Hepatocellular Carcinoma in Chinese Patients. 2020 , 7, 219-232		6
294	Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. 2020 , 20, 483		1
293	An international expert consensus of management of recurrent hepatocellular carcinoma: a viewpoint. 2020 , 9, 394-396		
292	IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. 2020 , 35, 1813-1820		0
291	Serum Zinc Level Grading System: A Useful Model for Composite Hepatic Events in Hepatitis C Virus-Associated Liver Cirrhosis. 2020 , 9,		1
290	Post-Treatment M2BPGi Level and the Rate of Autotaxin Reduction are Predictive of Hepatocellular Carcinoma Development after Antiviral Therapy in Patients with Chronic Hepatitis C. 2020 , 21,		1
289	Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMTT-HCC. <i>Hepatology Research</i> , 2020 , 50, 1004-1014	5.1	12
288	Resection of Mixed Hepatocellular-Cholangiocarcinoma, Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma. 2020 , 26, 888-898		7
287	Endoscopic ultrasound-guided radiofrequency ablation of porcine liver. 2020 , 47, 435-443		1
286	Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study. 2020 , 12,		17
285	Grip Strength: A Useful Marker for Composite Hepatic Events in Patients with Chronic Liver Diseases. 2020 , 10,		9
284	Late Evening Snack with Branched-Chain Amino Acids Supplementation Improves Survival in Patients with Cirrhosis. 2020 , 9,		7
283	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. 2021 , 73 Suppl 1, 158-191		63
282	Imaging of hepatocellular carcinoma: a pilot international survey. 2021 , 46, 205-215		2

281	Utility of serological tumor biomarkers for surveillance of hepatocellular carcinoma in patients undergoing dialysis. 2021 , 36, 1097-1103		2
280	Zinc deficiency predicts overt hepatic encephalopathy and mortality in liver cirrhosis patients with minimal hepatic encephalopathy. <i>Hepatology Research</i> , 2021 , 51, 662-673	5.1	4
279	Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study. <i>Hepatology Research</i> , 2021 , 51, 461-471	5.1	11
278	Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. 2021 , 120, 1051-1060		18
277	ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma. 2021 , 27, 1150-1161		14
276	Rate of hepatocellular carcinoma diagnosis in cirrhotic patients with ultrasound-detected liver nodules. 2021 , 16, 949-955		
275	Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA. 2021 , 36, 1118-1125		10
274	A Blood-Based Prognostic Liver Secretome Signature and Long-Term Hepatocellular Carcinoma Risk in Advanced Liver Fibrosis.		
273	Predictors for Grip Strength Loss in Patients With Chronic Liver Diseases. 2021 , 35, 363-371		1
272	Current status of image-based surveillance in hepatocellular carcinoma. 2021 , 40, 45-56		3
271	Recent advances in the surgical management of hepatocellular carcinoma. 2021 , 34, 453-465		1
270	Reply to the Letter "Comment on Regarding Manuscript 'Treatment of Intermediate Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies'". 2021 , 10, 163		
269	Factors Associated With Longitudinal QOL Change in Patients With Chronic Liver Diseases. 2021 , 35, 2451-2456		
268	Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis. 2021 , 27, 64-72		2
267	Preliminary clinical study of the safety of hepatectomy predicted by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced T1 mapping magnetic resonance imaging. 2021 , 5, 382-389		1
266	Computed Tomography-Measured Liver Volume Predicts the Risk of Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients. 2021 , 66, 4536-4544		
265	Treatment of intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. 2021 , 5, 538-552		1
264	Consensus report from the 9 International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. 2021 , 31, 5615-5628		3

263	Carbon ion radiotherapy for patients with hepatocellular carcinoma in the caudate lobe carbon ion radiotherapy for hepatocellular carcinoma in caudate lobe. <i>Hepatology Research</i> , 2021 , 51, 303-312	5.1	2
262	The Recent Development of the Surgical Treatment for Hepatocellular Carcinoma. 2021 , 11, 2023		1
261	Perioperative Geriatric Assessment as A Predictor of Long-Term Hepatectomy Outcomes in Elderly Patients with Hepatocellular Carcinoma. 2021 , 13,		1
260	Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. 2021 , 73, e3349-e3354		3
259	Clinical Benefits of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma. 2021 , 11, 1882		1
258	Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward?. 2021 , 10,		2
257	Clinical Application of Liver Imaging Reporting and Data System for Characterizing Liver Neoplasms: A Meta-Analysis. 2021 , 11,		4
256	Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta-analysis. 2021 , 41, 1117-1128		6
255	Modified albumin-bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients. 2021 , 26, 922-932		2
254	Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. 2021 , 16, e0247728		1
253	External Beam Radiotherapy for Hepatocellular Carcinoma: a Review of the Current Guidelines in the East and the West. 2021 , 21, 25-33		1
252	Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells. 2021 , 549, 171-178		3
251	Combined grip strength and calf circumference as a useful prognostic system in patients with liver diseases: a large cohort study. 2021 , 9, 624		1
250	Effect of Diameter and Number of Hepatocellular Carcinomas on Survival After Resection, Transarterial Chemoembolization, and Ablation. 2021 , 116, 1698-1708		2
249	Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. 2021 , 15, 663-675		9
248	Age-dependent decrease of hepatic geranylgeranoic acid and its oral supplementation prevents spontaneous hepatoma in C3H/HeN mice.		
247	Hepatobiliary contrast agents in MR: Where we stand and future perspectives. 2021 , 41, 888-890		
246	Is There a Place for Elastography in the Diagnosis of Hepatocellular Carcinoma?. 2021 , 10,		0

245	Serum Levels of ITGBL1 as an Early Diagnostic Biomarker for Hepatocellular Carcinoma with Hepatitis B Virus Infection. 2021 , 8, 285-300	2
244	Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma. 2021 , 28, 7663-7672	9
243	Prediction of Hepatocellular Carcinoma by Liver Stiffness Measurements Using Magnetic Resonance Elastography After Eradicating Hepatitis C Virus. 2021 , 12, e00337	1
242	Association of Albumin-Bilirubin Grade and Sequential Treatment with Standard Systemic Therapies for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Using a Japanese Administrative Database. 2021 , 8, 301-314	1
241	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. 2021 , 156, 463.e1-463.e30	2
240	Myostatin as a fibroblast-activating factor impacts on postoperative outcome in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2021 , 51, 803-812	5-1 3
239	Salvage hepatectomy for local recurrence after particle therapy using proton and carbon ion beams for liver cancer. 2021 , 5, 711-719	0
238	Role of modern radiotherapy in managing patients with hepatocellular carcinoma. 2021 , 27, 2434-2457	5
237	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. 2021 , 156, 463.e1-463.e30	0
236	Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation. 2021 , 76, 333-341	1
235	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. 2021 , 10, 181-223	38
234	Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: Radiologic and Clinical Factors Predictive of Survival. 2021 , 216, 1566-1573	3
233	Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification. 2021 , 21, 668	1
232	Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. 2021 , 36, 2943-2951	1
231	Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. 2021 , 15, 155-160	3
230	Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery?. 2021 , 27, 2784-2794	4
229	Prediction of Early Recurrence After Surgery for Liver Tumor (ERASL): An International Validation of the ERASL Risk Models. 2021 , 28, 8211-8220	2
228	Prognostic Impact of Lymphocyte-C-Reactive Protein Ratio in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma. 2021 , 1	3

227	Systemic therapy for hepatocellular carcinoma: current status and future perspectives. 2021 , 51, 1363-1371	0
226	Serum alpha-fetoprotein increases prior to fibrosis resolution in a patient with acute liver failure. 2021 , 14, 1470-1475	0
225	Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma - 2020 Guangzhou Recommendations. 2021 , 11, 621834	1
224	Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. 2021 , 21, 306	5
223	Liver Imaging Reporting and Data System: Review of Pros and Cons. 2021 ,	0
222	A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. 2021 , 2, 836-850.e10	3
221	Indications of Laparoscopic Repeat Liver Resection for Recurrent Hepatocellular Carcinoma.. 2022 , 6, 119-126	0
220	Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report. 2021 , 11,	0
219	Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals. 2021 ,	
218	Treatments of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Current Status and Controversy.. 2022 , 10, 147-158	4
217	Role of Ultrasound for Chronic Liver Disease and Hepatocellular Carcinoma Surveillance. 2021 , 29, 279-290	
216	New next-generation microwave thermosphere ablation for small hepatocellular carcinoma. 2021 , 27, 564-574	2
215	Handgrip strength stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis. 2021 ,	3
214	Magnetic Resonance Imaging for Surveillance of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. 2021 , 11,	2
213	Differences in radiotherapy application according to regional disease characteristics of hepatocellular carcinoma. 2021 , 21, 113-123	1
212	Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival. 2021 , 99, 756-765	0
211	Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. 2021 , 11, 709278	1
210	Risk stratification of hepatocellular carcinoma in patients with chronic liver disease by combining gadolinium-ethoxybenzyl diethylenetriamine-pentaacetic acid-enhanced magnetic resonance imaging and magnetic resonance elastography.	0

209	Age-Dependent Decrease in Hepatic Geranylgeranoic Acid Content in C3H/HeN Mice and Its Oral Supplementation Prevents Spontaneous Hepatoma. 2021 , 11,		1
208	Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice. 2021 , 1		3
207	Hepatocellular Carcinoma: Diagnosis and Surveillance.		0
206	Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. 2021 ,		2
205	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. 2021 , 9,		9
204	Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?. 2021 , 27, 5536-5554		3
203	Advanced hepatocellular carcinoma treated by radiofrequency ablation combined with oncolytic virus and anti-PD-1 antibody therapy: a case report and literature review. 2021 , 49, 3000605211044596		0
202	Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis. <i>Hepatology Research</i> , 2021 , 51, 1219-1228	5.1	0
201	Comparative Analysis of Lenvatinib and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-Center, Propensity Score Study. 2021 , 10,		1
200	Analysis of the Current Status of Liver Cancer Screening Institutions and Proficiency of Institutions that Conduct Alpha-fetoprotein Tests. 2021 , 11, 245-253		
199	Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. 2021 , 25, 785-803		2
198	Recurrent hepatogastric fistula during lenvatinib therapy for advanced hepatocellular carcinoma managed by over-the-scope clip closure: a case report. 2021 , 16, 102-110		
197	Hepatic Resection for Hepatocellular Carcinoma in the Era of Molecular-targeted Agents and Immune Checkpoint Inhibitors in Japan. 2021 , 4, 241-245		0
196	The Management of Recurrence of Hepatocellular Carcinoma Occurring Within 6 Months After Hepatic Resection: A Comparative Study Using a Propensity Score Matching Analysis. 2021 , 1		1
195	Effectiveness of individual audio-visual coaching, respiratory modulated stereotactic body radiotherapy for localized hepatocellular carcinoma: Analysis of 29 cases from a single academic radiotherapy center. 2021 , 33, 380-387		
194	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). 2021 , 10, 451-460		3
193	A case of hypervascular tumors in the liver and pancreas: synchronous hepatocellular carcinoma and pancreatic metastasis from renal cell carcinoma 36 years after nephrectomy. 2021 , 9, 932-937		2
192	Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report. 2020 , 13, 428-433		6

191	Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. 2020 , 9, 640-662	36
190	Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. 2020 , 6,	7
189	Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI. 2020 , 6,	6
188	Switching to systemic therapy after locoregional treatment failure: Definition and best timing. 2020 , 26, 155-162	21
187	Novel biomarkers for the management of chronic hepatitis B. 2020 , 26, 261-279	28
186	Difference in treatment algorithms for hepatocellular carcinoma between world's principal guidelines. 2020 , 2, 282-291	4
185	What liver surgeons have achieved in the recent decade for patients with hepatocellular carcinoma?. 2020 , 2, 265-268	2
184	Early hemodynamics of hepatocellular carcinoma using contrast-enhanced ultrasound with Sonazoid: focus on the pure arterial and early portal phases. 2020 , 2, 319-327	1
183	Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. 2020 , 14, 515	1
182	Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report. 2020 , 12, 1349-1357	4
181	Aberrant expression of two miRNAs promotes proliferation, hepatitis B virus amplification, migration and invasion of hepatocellular carcinoma cells: evidence from bioinformatic analysis and experimental validation. 2020 , 8, e9100	3
180	Diagnosis and Evaluation of Hepatocellular Carcinoma. 2021 , 1-22	
179	Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. 2021 ,	0
178	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. 2021 , JCO2100608	15
177	Prediction model for hepatocellular carcinoma occurrence in patients with hepatitis C in the era of direct-acting anti-virals. 2021 , 54, 1340-1349	4
176	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. 2021 , 13,	1
175	Three Cases of Hepatocellular Carcinoma With Massive Macrovascular Invasion Successfully Treated With Radiotherapy. 2021 , 13, e18624	
174	Operative Microwave Ablation for Hepatocellular Carcinoma Within 3cm and 3 Nodules: Experience in 559 Patients. 2021 , 1	1

173	Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma. 2021 , 13, 1245-1257	1
172	The Combination of Albumin-Bilirubin Score and Prothrombin Time Is a Useful Tool for Predicting Liver Dysfunction after Transcatheter Arterial Chemoembolization in Child-Pugh Class A Patients with Hepatocellular Carcinoma within Up-to-Seven Criteria. 2021 , 10,	0
171	Prevalence of the Absence of Cirrhosis in Subjects with NAFLD-Associated Hepatocellular Carcinoma. 2021 , 10,	1
170	Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis. 2021 , 1	1
169	Roles of Tumor Markers in Diagnosis and Treatment of Hepatocellular Carcinoma. 2020 , 95, 31-35	
168	COVID-19?????????????????????????????????????. 2020 , 61, 389-398	
167	Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. 2021 , 13,	0
166	Liver resection is associated with good outcomes for hepatocellular carcinoma patients beyond the Barcelona Clinic Liver Cancer criteria: A multicenter study with the Hiroshima Surgical study group of Clinical Oncology. 2021 ,	0
165	Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study. 2021 ,	3
164	Optimal Modalities for HCC Surveillance in a High-Incidence Region. 2020 , 16, 236-239	
163	Propofol midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma. 2021 , 5, 273-279	1
162	Selection of patients with esophageal varices for liver resection of hepatocellular carcinoma. 2021 , 14, 436-442	0
161	Simple Stratification of Hepatocellular Carcinoma Surveillance after Direct-acting Antiviral Therapy for Chronic Hepatitis C. 2020 , 32, 125-133	
160	Current Status of Hepatocellular Carcinoma Occurrence after Achieving a Sustained Virologic Response with Direct-Acting Antiviral Drug Treatment for Type C Chronic Liver Disease: A Study at Kawasaki Municipal Tama Hospital. 2020 , 11, 143-152	
159	Mac-2-Binding Protein Glycosylation Isomer as a Novel Predictor of Hepatocellular Carcinoma Recurrence in Patients with Hepatitis C Virus Eradication. 2021 ,	0
158	Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. 2020 , 2, 273-281	0
157	Single Large Nodule (>5 cm) Prognosis in Hepatocellular Carcinoma: Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B?. 2020 , 26, e926797	
156	A validation study of combined resection and ablation therapy for multiple hepatocellular carcinoma. 2021 ,	0

155	The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: a prospective United Kingdom cohort study. 2021 , 12, 2338-2350	1
154	Changes in therapeutic options for hepatocellular carcinoma in Asia. 2021 ,	1
153	[Current Status and Future Directions of Hepatocellular Carcinoma Surveillance Test Based on Cost-effective Analysis]. 2021 , 78, 255-260	0
152	Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study. 2021 , 11, 729764	4
151	Combination of psoas muscle mass index and neutrophil/lymphocyte ratio as a prognostic predictor for patients undergoing nonsurgical hepatocellular carcinoma therapy.. 2021 , 5, 1335-1343	2
150	Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. 2021 , 22,	1
149	Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma.. 2021 , 11, 726213	4
148	Higher Accumulation of Visceral Adipose Tissue Is an Independent Risk Factor for Hepatocellular Carcinoma among Viral Hepatitis Patients with Non-Cirrhotic Livers. 2021 , 13,	0
147	Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. 2021 ,	6
146	Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination. 2021 , 55, 422	3
145	A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma.. 2021 , 10, 3553-3560	2
144	Single Large Nodule (>5 cm) Prognosis in Hepatocellular Carcinoma: Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B?. 2020 , 26, e926797	0
143	Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents.. 2022 , 57, 90	0
142	Medical Treatment for Hepatocellular Carcinoma in Japan.. 2022 ,	1
141	Comparison of Ablation Area and Change in Functional Liver Reserve after Radiofrequency Ablation for Hepatocellular Carcinoma Using the arfa and VIVA Systems.. 2022 , 11,	1
140	A novel combined prognostic nutritional index and aspartate aminotransferase-to-platelet ratio index-based score can predict the survival of patients with hepatocellular carcinoma who undergo hepatic resection.. 2022 , 1	0
139	Preventing Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy With Active Hexose-correlated Compound Derived From Lentinula edodes Mycelia.. 2022 , 21, 15347354211073066	
138	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.. 2022 , 23, 77-90	58

137	Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.. 2022 , 57, 120	0
136	Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.. 2022 , 211545	3
135	Validity of the Algorithm for Liver Resection of Hepatocellular Carcinoma in the Caudate Lobe.. 2022 ,	
134	Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality.. 2021 ,	8
133	Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients.. 2022 , 22, 175	1
132	Will the collaboration of surgery and external radiotherapy open new avenues for hepatocellular carcinoma with portal vein thrombosis?. 2022 , 28, 704-714	0
131	The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update.. 2022 , 16,	3
130	The impact of background liver disease on the long-term prognosis of very-early-stage HCC after ablation therapy.. 2022 , 17, e0264075	
129	Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.. 2022 ,	2
128	Predicting Complications following Surgical Resection of Hepatocellular Carcinoma Using Newly Developed Neo-Glasgow Prognostic Score with ALBI Grade: Comparison of Open and Laparoscopic Surgery Cases.. 2022 , 14,	0
127	Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis.. 2022 , 11,	
126	Successful treatment with laparoscopic surgery and sequential multikinase inhibitor therapy for hepatocellular carcinoma: A case report.. 2022 , 14, 260-267	
125	Intended preoperative trans-arterial embolization for large hepatocellular carcinoma: a retrospective cohort study.. 2022 , 20, 90	1
124	Prediction Model for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Primary Hepatocellular Carcinoma 2cm or Smaller.. 2022 , 1	
123	Hepatocellular carcinoma effective stereotactic body radiotherapy using Gold Anchor and the Synchrony system: Two case reports and review of literature.. 2022 , 10, 2591-2603	
122	Elevated expression of RAB3B plays important roles in chemoresistance and metastatic potential of hepatoma cells.. 2022 , 22, 260	0
121	Isatin Counteracts Diethylnitrosamine/2-Acetylaminofluorene-Induced Hepatocarcinogenesis in Male Wistar Rats by Upregulating Anti-Inflammatory, Antioxidant, and Detoxification Pathways.. 2022 , 11,	2
120	Development and Validation of a Prediction Model for Predicting the Prognosis of Postoperative Patients with Hepatocellular Carcinoma.. 2022 , 15, 3625-3637	0

119	A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response.. 2022 , 6, 20-28	0
118	Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.. 2022 , 11, 48-60	1
117	Update on perioperative management of patients undergoing surgery for liver cancer.	
116	Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study.. 2021 , 8, 1565-1577	1
115	Liver Transplantation for Malignant Liver Tumors. 2022 ,	
114	Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan.. 2022 , 12, 6479	1
113	Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.. 2022 ,	1
112	Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment.	0
111	Recent advances in medical treatment of hepatocellular cancer. 2022 , 365-375	
110	The Impact of Cirrhosis and History of Hepatocellular Carcinoma on All-Cause Mortality After Eradication of Hepatitis C Virus in Patients With Chronic Hepatitis C. 2022 , 1, 508-515	
109	Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.. 2022 ,	1
108	Comparison of the New Neo-Glasgow Prognostic Score Based on the Albumin-Bilirubin Grade with Currently Used Nutritional Indices for Prognostic Prediction following Surgical Resection of Hepatocellular Carcinoma: A Multicenter Retrospective Study in Japan.. 2022 , 14,	0
107	Application and progress of the detection technologies in hepatocellular carcinoma. 2022 ,	2
106	Limitations of Nerve Fiber Density as a Prognostic Marker in Predicting Oncological Outcomes in Hepatocellular Carcinoma.. 2022 , 14,	0
105	New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.. 2022 , 1	2
104	Survival benefit of L-carnitine supplementation in patients with cirrhosis.. 2022 ,	0
103	Impact of antiviral therapy for disease progression and non-invasive liver fibrosis index in patients with chronic hepatitis C: Markov chain model analysis.. <i>Hepatology Research</i> , 2022 ,	5.1 0
102	The role of re-resection in recurrent hepatocellular carcinoma.	0

- 101 Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C who achieved a sustained virological response through direct-acting antiviral agents among the working population in Japan.
- 100 Il Consenso mexicano de carcinoma hepatocelular. Parte II: tratamiento. **2022**,
- 99 Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. ○
- 98 General evaluation score for predicting the development of hepatocellular carcinoma in patients with advanced liver fibrosis associated with hepatitis C virus genotype 1 or 2 after direct-acting antiviral therapy.
- 97 Conversion Therapy of Large Unresectable Hepatocellular Carcinoma With Ipsilateral Portal Vein Tumor Thrombus Using Portal Vein Embolization Plus Transcatheter Arterial Chemoembolization. 12,
- 96 Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma. ○
- 95 Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct-acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance.
- 94 Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis 113 characteristics (excluding spaces). *Hepatology Research*, 5.1 ○
- 93 Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in chronic liver disease rats and humans.
- 92 Long-term outcomes of living-donor liver transplantation, hepatic resection, and local therapy for hepatocellular carcinoma with three ≤ 3-cm nodules in a single institute.
- 91 Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis. **2022**, 34, 857-864 ○
- 90 Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition. **2022**, 14, 528-537
- 89 The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment. **2022**,
- 88 Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). ○
- 87 Diagnosis and pathological analysis of sarcopenia in chronic liver disease using liver MRI. **2022**, 63, 305-318
- 86 Impairment of perioperative activities of daily living is associated with poor prognosis following hepatectomy for hepatocellular carcinoma. ○
- 85 Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma. **2022**, 14, 1480-1494
- 84 Immune Evasion of Hepatoma Cancer Stem-Like Cells from Natural Killer Cells. ○

- 83 Sustained Virological Response Is the Most Effective in Preventing Hepatocellular Carcinoma Recurrence after Curative Treatment in Hepatitis C Virus-Positive Patients: A Study Using Decision Tree Analysis. **2022**, 2, 345-354
- 82 Stereotactic Body Radiation Therapy for the Management of Hepatocellular Carcinoma: Efficacy and Safety. **2022**, 14, 3892
- 81 Risk factors for liver-related mortality of patients with hepatitis C virus after sustained virologic response to direct-acting antiviral agents.
- 80 Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma via the tumor immune microenvironment analysis. 13,
- 79 Impact of aspartate aminotransferase to platelet ratio index based score to assess posthepatectomy liver failure in patients with hepatocellular carcinoma. **2022**, 20,
- 78 Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma. **2022**, 28, 3917-3933 1
- 77 The prognostic potential of fragmented CK18 serum levels in HCC patients reflecting disease progression and overall hepatocyte damage. 12,
- 76 Current status of liver transplantation for non-B non-C liver cirrhosis and hepatocellular carcinoma.
- 75 Protein Kinase C delta Is a Novel Biomarker for Hepatocellular Carcinoma. **2022**, ○
- 74 Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE). ○
- 73 Management of hepatocellular carcinoma in patients who are 70 years or older. **2022**, 10, 53-58
- 72 Alanine aminotransferase levels as therapeutic targets after nucleotide/nucleoside analogue therapy in chronic hepatitis B patients. ○
- 71 Surveillance for hepatocellular carcinoma: It is time to move forward. ○
- 70 Outcomes of Interferon-free Treatment of Hepatitis C Virus Infection Seven Years after Approval and Problems with Drop out during and after Treatment: A Retrospective, Single-center Study. **2022**, ○
- 69 Diagnosis and Evaluation of Hepatocellular Carcinoma. **2022**, 27-48 ○
- 68 Antitumor Effect of Zinc Acetate in Hepatocellular Carcinoma Cell Lines via the Induction of Apoptosis. **2022**, 68, 303-311 ○
- 67 Hepatectomy is Beneficial in Select Patients with Multiple Hepatocellular Carcinomas. ○
- 66 Image quality of abdominal ultrasonography after esophagogastroduodenoscopy is preserved by using carbon dioxide insufflation: A non-inferiority test in the same subject. **2022**, 17, e0275257 ○

65	ASO Author Reflections: Hepatectomy for Multiple Hepatocellular Carcinomas.	0
64	The Application of Liquid Biopsy Techniques in High-Risk Population for Hepatocellular Carcinoma. Volume 14, 2735-2748	0
63	Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.	0
62	Subcutaneous Fat Thickness of the Lower Limb is Associated with Trunk Muscle Mass in Patients with Hepatocellular Carcinoma: A Simple Assessment for Sarcopenia Using Conventional Ultrasonography. 2022,	0
61	Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab+bevacizumab treatment for hepatocellular carcinoma.	1
60	Reevaluation of Makuuchi's criteria for resecting hepatocellular carcinoma: A Japanese Nationwide Survey.	1
59	Association of lithocholic acid with skeletal muscle hypertrophy through TGR5-IGF-1 and skeletal muscle mass in cultured mouse myotubes, chronic liver disease rats and humans. 11,	0
58	Positive predictive value of LI-RADS US-3 observations: multivariable analysis of clinical and imaging features.	0
57	Dynamics of type IV collagen 7S fragment on eradication of HCV with direct antiviral agents: Prognostic and metabolomic impacts. 2022, 17, e0276925	0
56	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. 2022, 28, 583-705	3
55	Modified Albumin-Bilirubin Grade and Alpha-Fetoprotein Score (mALF Score) for Predicting the Prognosis of Hepatocellular Carcinoma after Hepatectomy. 2022, 14, 5292	0
54	Artificial intelligence (AI) models for the diagnosis and management of liver diseases.	0
53	Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.	0
52	The prognostic role of controlling nutritional status and skeletal muscle mass in patients with hepatocellular carcinoma after curative treatment. 2022, 34, 1269-1276	0
51	Comparison of Surgical Resection and Percutaneous Ultrasonographic Guided Radiofrequency Ablation for Initial Recurrence of Hepatocellular Carcinoma in Early Stage following Curative Treatment. 2022, 14, 5524	0
50	Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.	1
49	Clinical effectiveness of transcatheter arterial chemoembolization sequential microwave ablation for lack of blood supply in hepatocellular carcinoma.	0
48	Personalized Prognostic Model (Contour Prognostic Model). 2022, 253-259	0

47	Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials. 2022 , 21, 153303382211173	0
46	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2022 , 23, 1126	4
45	A simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosis. 2022 , 17, e0277829	0
44	Recurrence of hepatocellular carcinoma after radiofrequency ablation in a poor-risk patient with chronic renal failure and other complications successfully treated with stereotactic body radiotherapy.	0
43	Effect of albumin measurement methods on the albuminBilirubin grade. 000456322211436	0
42	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.	0
41	Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients. 12,	0
40	Surgical Outcomes for Hepatocellular Carcinoma in Patients with ChildBugh Class B: a Retrospective Multicenter Study.	0
39	Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis. 2022 , 17, e0279416	0
38	Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma. 2022 , 14, 6089	1
37	Clinical practice guideline and real-life practice in hepatocellular carcinoma: Chinese perspective.	0
36	Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis.	0
35	Tumor stiffness measurement using magnetic resonance elastography can predict recurrence and survival after curative resection of hepatocellular carcinoma. 2022 ,	0
34	Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. 2023 , 15, 50	0
33	Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitisC virus patients with decompensated cirrhosis.	0
32	Hepatic arterial infusion chemotherapy in hepatocellular carcinoma: A bibliometric and knowledge-map analysis. 12,	0
31	Effect of fatty liver and fibrosis on hepatocellular carcinoma development in patients with chronic hepatitis B who received nucleic acid analog therapy.	0
30	Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan.	0

- 29 Effect of blood product transfusion on the prognosis of patients undergoing hepatectomy for hepatocellular carcinoma: a propensity score matching analysis. 1
- 28 Positioning of Minimally Invasive Liver Surgery for Hepatocellular Carcinoma: From Laparoscopic to Robot-Assisted Liver Resection. **2023**, 15, 488 0
- 27 Surgical Strategies for Recurrent Hepatocellular Carcinoma after Resection: A Review of Current Evidence. **2023**, 15, 508 0
- 26 HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis. **2022**, 101, e32390 0
- 25 Role of magnetic resonance elastography in the management of liver-related events in advanced chronic liver disease. **2023**, 64, 44-58 0
- 24 Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma—Consideration of the Locations of Target Lesions. **2023**, 15, 846 0
- 23 Understanding the differences between Japanese and U.S. guidelines on clinical practice for contrast-enhanced ultrasound of the liver. **2023**, 50, 1-3 0
- 22 A nationwide propensity score analysis comparing ablation and resection for hepatocellular carcinoma. 0
- 21 Impact of skeletal muscle volume on patients with BCLC stage-B hepatocellular carcinoma undergoing sorafenib therapy. 0
- 20 Treatment of recurrent hepatocellular carcinoma following liver resection, ablation or liver transplantation. 11, 47-54 0
- 19 Transcriptome analysis creates a new era of precision medicine for managing recurrent hepatocellular carcinoma. 29, 780-799 0
- 18 Protocol of the RACB study: A multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.. 0
- 17 Multiplication of tumor maximum diameter and number as a new surgical indicator for Barcelona Clinic Liver Cancer intermediate-stage hepatocellular carcinoma. 0
- 16 Stationary Trend in Elevated Serum Alpha-Fetoprotein Level in Hepatocellular Carcinoma Patients. **2023**, 15, 1222 0
- 15 Disease-Free Interval and Tumor Stage Complementarily Predict the Biological Behavior of Recurrent Hepatocellular Carcinoma. 0
- 14 Breakthroughs in Hepatocellular Carcinoma Therapies. **2023**, 0
- 13 Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review. **2023**, 24, 4286 1
- 12 Short and long-term outcomes after minimally invasive liver resection for single small hepatocellular carcinoma: An analysis of 714 patients from the IGoMILS (Italian group of minimally invasive liver surgery) registry. **2023**, 0

- 11 Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). ○
- 10 Noninvasive assessments of liver disease severity based on biomarkers. **2023**, 31-60 ○
- 9 Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada. **2023**, 115, 102526 ○
- 8 Clinical role of radiofrequency ablation for early-stage hepatocellular carcinoma in an advanced aging society. ○
- 7 Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective. **2023**, 29, 242-251 ○
- 6 Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma. **2023**, 23, ○
- 5 Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group. ○
- 4 A radiographic tumor burden score-based preoperative model to predict overall survival in patients with hepatocellular carcinoma undergoing resection□ ○
- 3 Surgical resection for large hepatocellular carcinoma and those beyond BCLC: systematic review with proposed management algorithm. **2023**, 408, ○
- 2 Improving the sensitivity of liver tumor classification in ultrasound images <i>via&/i> a power-law shot noise model. **2023**, ○
- 1 Effectiveness of CT-image guidance in proton therapy for liver cancer and the importance of daily dose monitoring for tumors and organs at risk. ○